Agios Pharmaceuticals (AGIO) Net Cash Flow Growth (3y) (2015 - 2026)
Agios Pharmaceuticals (AGIO) Net Cash Flow Growth (3y) (2015 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | NCF Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,681.27 Bn | 66,680.98 Bn | - | -50.33% |
| 2 | Nanobiotix | 1,905.61 Bn | 1,905.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,011.81 Bn | 1,011.81 Bn | - | - |
| 4 | BeOne Medicines | 467.29 Bn | 462.50 Bn | 1.35 Bn | 38.47% |
| 5 | Vertex Pharmaceuticals | 122.89 Bn | 115.65 Bn | 2.59 Bn | 33.37% |
| 6 | Regeneron Pharmaceuticals | 70.28 Bn | 61.53 Bn | 3.31 Bn | -29.82% |
| 7 | Belite Bio | 62.93 Bn | 62.93 Bn | - | - |
| 8 | Argenx Se | 55.90 Bn | 50.72 Bn | 1.41 Bn | - |
| 9 | Alnylam Pharmaceuticals | 37.64 Bn | 34.63 Bn | 959.66 Mn | 32.17% |
| 10 | Agios Pharmaceuticals | 2.22 Bn | 1.49 Bn | 19.43 Mn | 39.19% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 39.19% |
| Dec 31, 2025 | -30.31% |
| Sep 30, 2025 | -29.58% |
| Jun 30, 2025 | -39.28% |
| Mar 31, 2025 | 26.45% |
| Dec 31, 2024 | 3.43% |
| Sep 30, 2024 | 27.43% |
| Jun 30, 2024 | 65.99% |
| Mar 31, 2024 | -74.26% |
| Dec 31, 2023 | -29.93% |
| Sep 30, 2023 | 65.05% |
| Jun 30, 2023 | -27.64% |
| Mar 31, 2023 | -84.72% |
| Dec 31, 2022 | 186.87% |
| Sep 30, 2022 | 171.99% |
| Jun 30, 2022 | 34.42% |
| Mar 31, 2022 | -79.02% |
| Dec 31, 2021 | -31.86% |
| Sep 30, 2021 | -257.04% |
| Jun 30, 2021 | -78.09% |